ATRA ATARA BIOTHERAPEUTICS INC Investments/Divestments 8-K Filing 2024 - Securities Purchase Agreement and Nasdaq Deficiency Letter Atara Biotherapeutics, Inc. entered into a securities purchase agreement to issue and sell pre-funded warrants in a registered direct offering, expected to raise approximately $15.0 million, and received a deficiency letter from Nasdaq regarding the bid price for its common stock.Get access to all SEC 8-K filings of the ATARA BIOTHERAPEUTICS INC